Contrary to U.S. guidelines, early action against high BP in patients exhibiting signs of hypertension doesn’t reduce their risk of heart disease later in life, according to a study published in the European Heart Journal Nov. 21.

Although nearly a quarter of patients in a U.S. registry study died in the year following transcatheter mitral valve repair (TMVR), those who survived showed significant gains in health status.

Infrastructure requirements and changing policy are the top barriers to speeding the adoption of value-based care, according to a survey of healthcare executives, clinical leaders and clinicians conducted by NEJM Catalyst.

A new expert consensus document from the American College of Cardiology singled out liraglutide and empagliflozin as the preferred drugs in their classes to reduce cardiovascular risk among patients with type 2 diabetes and atherosclerotic cardiovascular disease.

Smoke-free policies in public places like bars and restaurants were linked to lower systolic blood pressures (SBPs) among participants from the longitudinal CARDIA study, according to new research published in the Journal of the American Heart Association.

CT analysis prior to percutaneous pulmonary valve implantation (PPVI) in patients with congenital heart disease (CHD) could help physicians detect which individuals are at the greatest risk for coronary artery compression during the procedure, according to research published ahead of print in the European Journal of Radiology.

When consumers think of wearable personal health devices, they likely picture smartwatches or other wrist-worn gadgets. But as Forbes pointed out in a Nov. 26 article, new headphone-type wearables—dubbed “hearables”—have already grown into a $5 billion market and offer unique capabilities.

Santa Monica, CA, Nov. 27, 2018 - BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has signed an agreement with Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center in Austin, Texas, to conduct First-in-Human studies using the PURE EP™ System.

Almost 1 in 5 patients are rehospitalized within 30 days of undergoing catheter ablation of MI-associated ventricular tachycardia (VT), according to a study from the Nationwide Readmissions Database. These patients rack up 38.9 percent higher cumulative hospital costs than those who aren’t readmitted, researchers reported in Circulation: Arrhythmia and Electrophysiology.

A Michigan-based hospital system rejected a patient's request for a heart transplant with the suggestion she fundraise $10,000 to pay for medications, touching off a debate about Medicare for all and the costs of American healthcare in general.